Trifluridine-Tipiracil
Lonsurf is a prescription brand-name medication used to treat adults with metastatic colorectal cancer or metastatic gastric/gastroesophageal junction adenocarcinoma who have previously received standard treatments. It is a combination of two drugs that work together to inhibit cancer cell growth.
Lonsurf is a chemotherapy medication for advanced colorectal and gastric cancers that have progressed after prior treatment.
Key facts at a glance
- RxNorm
- 1670317
- Generic
- Lonsurf
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Lonsurf is indicated for the treatment of adults with metastatic colorectal cancer who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, and if applicable, anti-VEGF therapy and anti-EGFR therapy. It is also used for metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have received prior treatment with at least two chemotherapy regimens.
Lonsurf contains two active ingredients: trifluridine and tipiracil. Trifluridine is incorporated into DNA during cell replication, interfering with DNA synthesis and inhibiting cell proliferation. Tipiracil is a thymidine phosphorylase inhibitor that prevents the breakdown of trifluridine, thereby maintaining effective drug levels in the body.
Lonsurf may cause serious side effects including bone marrow suppression (anemia, neutropenia, thrombocytopenia), gastrointestinal symptoms (nausea, vomiting, diarrhea), and fatigue. Regular blood monitoring is required during treatment. The medication should be taken with food and dosing is based on body surface area. Patients should avoid pregnancy during treatment as it may cause harm to a developing fetus.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy